Clinical trials

#AI #Cancer research #Clinical trials #Molecular medicine #Precision medicine

Study highlights real-world impact of AI platform in precision medicine 

Exscientia, the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences has published final results from the EXALT-1 trial in Cancer Discovery.  The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,” illustrates the potential… Read More

#Cancer Research #News

#Cellular imaging #Clinical trials #Data #Imaging

Medidata hits platform milestone  

Medidata’s Rave Imaging, the company’s cloud-based, secure clinical trial imaging management platform, has now supported more than 1,000 imaging studies.   Rave Imaging processes more than 100 million images annually. The technology provides real-time visibility into imaging-related trial activities to enhance study efficiency.   Paul McCracken, VP and… Read More

#News

#Clinical trials #ELRIG #Healthcare #Public health

An inside perspective on the value of diversity in health research 

In DDW and ELRIG UK's Drug Discovery 2021 supplement, CEO and Founder of Egality Health, Annette Crosse, offers insight into the importance of diversity in clinical trials and of overcoming limitations in healthcare research to re-imagine a system which provides safe, effective and innovative therapies for the entire population.  Annette Crosse describes… Read More

#Editor's Choice #Exclusive Content #News

#Alzheimer's #Clinical trials #Drug candidates #Drug discovery

First patients dosed in Phase I study for Alzheimer’s

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase… Read More

#News #Trending News

#Cancer #Cancer immunotherapy #Cancer research #Clinical trials #Tumour biology

Cancer Awareness Month: Round up 

September 2021 has been Cancer Awareness Month for Blood, Childhood, Gynaecologic, Ovarian and Prostate Cancer, which affect millions of people around the world annually. Here is a round-up of eight of some of the innovative research and studies being done in order to tackle these various types of cancer. … Read More

#Cancer Research #News

#Clinical trials #FDA #Muscles

FDA Fast Track designation for limb-girdle muscular dystrophy 

BridgeBio has been granted Fast Track designation United States Food and Drug Administration (FDA) for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received in 2021.  BridgeBio’s LGMD2i investigational therapy… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Technology

DDW AI expert exclusive: Boosting innovation in medicine 

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development says Jeff Elton, CEO of Concerto HealthAI, who has extensive experience in this sector, and shares his insight with DDW.  In… Read More

#News

#Clinical trials #Covid-19 #Funding

iiCON secures over £150 million investment and creates 176 jobs   

The Infection Innovation Consortium (iiCON) is a global centre for infectious disease R&D and created 176 high-value jobs in the North West of the UK.   The consortium has raised £154.9 million in public and private investment in its first year – creating a £173.5 million programme. … Read More

#News

#Cancer research #Clinical trials #Institute of Cancer Research #Tumour biology

Promise in treatment-resistant advanced ovarian cancer 

A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial, shrinking tumours in half of patients. The combination of drugs, which both work by blocking signals cancer cells need to grow, could offer a new treatment option for women with… Read More

#Cancer Research #News #Trending News

#Cancer immunotherapy #Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Can Covid-19 vaccine technology be used for cancer vaccines?

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer.   Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More

#Cancer Research #Covid-19 #Editor's Choice #News

#Cancer #Clinical trials #Novel therapeutics #Oncology

CPRIT grant awarded to test potential large-molecule cancer drugs  

Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  Liu is Professor of Precision Biomedicine with… Read More

#Cancer Research #News

#Antibodies #Clinical trials #Data #Monoclonal antibodies

AstraZeneca Imfinzi combination effective with non-small cell lung cancer 

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had… Read More

#News

#Clinical trials #Collaboration #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical #Research

Early trial of first multivariant Covid-19 vaccine booster begins

A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust.  Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost… Read More

#News

#Biotechnology #Clinical trials #Research

Women’s antibiotic-free treatment trial reaches 50% recruitment 

Swedish company Gedea Biotech has announced that it has enrolled more than 50% of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomised double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University… Read More

#News

#Biomarkers #Clinical trials #Covid-19 #Pharma #Pneumonia #Research

Ruconest-treated patients test lower disease severity scores for Covid-19 

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven. … Read More

#News

#Biotechnology #Clinical trials #CRISPR #Market reporting #Therapeutics

Report predicts trends and forecasts for CRISPR 

The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.  The report features a study of the current market landscape and future opportunity for the players involved in the development of CRISPR… Read More

#Business & Investment #Market Reports #News #Trends & Analysis